

Under § 361.1(d)(8), the investigator will immediately report to the RDRC all adverse effects associated with use of the drug, and the committee will then report to FDA all adverse reactions probably attributed to the use of the radioactive drug.

Section 361.1(f) sets forth labeling requirements for radioactive drugs. These requirements are not in the reporting burden estimate because they are information supplied by the Federal Government to the recipient for the purposes of disclosure to the public (5 CFR 1320.3(c)(2)).

Types of research studies not permitted under the regulations are also

specified in § 361.1(a) and include those intended for immediate therapeutic, diagnostic, or similar purposes or to determine the safety or effectiveness of the drug in humans for such purposes (i.e., to carry out a clinical trial for safety or efficacy). These studies require filing of an IND under 21 CFR part 312, and the associated information collections, are covered in OMB control number 0910–0014.

The primary purpose of this collection of information is to determine whether the research studies are being conducted in accordance with applicable statutes and regulations specified under 21 CFR 361.1 and that

human subject safety is assured. If these studies were not reviewed, human subjects could be subjected to inappropriate radiation or pharmacologic risks. Respondents to this information collection are the chairperson or chairpersons of each individual RDRC, investigators, and participants in the studies. The burden estimates are based on our experience with these reporting and recordkeeping requirements and the number of submissions we received under the regulations over the past 3 years.

FDA estimates the burden of this collection of information as follows:

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN¹

21 CFR section and applicable form	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response	Total hours
§ 361.1(c)(3) reports and (c)(4) approval (Form FDA 2914: Membership Summary) ² .	55	1	55	1	55
§ 361.1(c)(3) reports (Form FDA 2915: Study Summary) ³ .	35	9	324	3.5	1,134
§ 361.1(d)(8) adverse events	10	1	10	.5 (30 minutes)	5
Total			389	1,194

¹ There are no capital costs or operating and maintenance costs associated with this collection of information.

² <https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM094979.pdf>.

³ <https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM074720.pdf>.

TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN¹

21 CFR section	Number of recordkeepers	Number of records per recordkeepers	Total annual records	Average burden per recordkeeping	Total hours
§ 361.1(c)(2) RDRC	55	4	220	10	2,200
§ 361.1(d)(5) human research subjects	35	9	324	.75 (45 minutes) ...	243
Total			544	2,443

¹ There are no capital costs or operating and maintenance costs associated with this collection of information.

Our estimated burden for the information collection reflects an overall decrease of 52 hours and a corresponding decrease of 97 responses. This is attributed to the Agency receiving fewer submissions over the last few years due to decreased subject enrollment during the pandemic.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–07507 Filed 4–16–26; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2026–N–3799]

Authorization of Emergency Use for Four Animal Drugs for the Treatment of New World Screwworm; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

SUMMARY: The Food and Drug Administration (FDA or the Agency) is announcing the issuance of four Emergency Use Authorizations (EUA) (Authorization) under the Federal Food, Drug, and Cosmetic Act (FD&C Act) for new animal products. FDA has issued three EUAs for animal products as requested by Boehringer Ingelheim

Animal Health USA, Inc. (Boehringer) for the prevention of infestations caused by New World screwworm (*Cochliomyia hominivorax*) (NWS) larvae (myiasis) in certain cattle, and for the treatment of such infestations in dogs, and cats. FDA has issued one EUA for an animal product as requested by Health and Hygiene (Pty) Ltd. for the prevention and treatment of infestations caused by NWS larvae (myiasis) in cattle, horses, minor species of hoof stock (e.g., sheep, goats, deer), raptors and other wild birds, pet birds, and captive wild, exotic, and zoo mammals. The Authorizations contain, among other things, conditions on the emergency use of the authorized products. The Authorizations follow the August 18, 2025, determination by the Secretary of Health and Human Services (HHS) that there is a significant potential for a public health emergency that has a

significant potential to affect national security or the health and security of U.S. citizens living abroad and that involves NWS. On the basis of such determination, the Secretary of HHS declared on August 18, 2025, that circumstances exist justifying the authorization of emergency use of animal drugs to treat or prevent NWS myiasis in animals. The Authorizations, which include an explanation of the reasons for issuance, are reprinted in this document.

DATES: The Authorizations are effective on their dates of issuance: February 5, 2026, February 18, 2026, and March 10, 2026, respectively.

ADDRESSES: Submit written requests for single copies of the EUAs to the Policy and Regulations Staff, Center for Veterinary Medicine, Food and Drug Administration, 5001 Campus Drive, College Park, MD 20740. Send one self-addressed adhesive label to assist that office in processing your requests. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the Authorizations.

FOR FURTHER INFORMATION CONTACT: Crystal Groesbeck, Center for Veterinary Medicine, Food and Drug Administration, 5001 Campus Drive, College Park, MD 20740, 240-402-0819, Crystal.Groesbeck@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Background

Section 564 of the FD&C Act (21 U.S.C. 360bbb-3) allows FDA to strengthen public health protections against biological, chemical, nuclear, and radiological agents. Among other things, section 564 of the FD&C Act allows FDA to authorize the use of an unapproved medical product or an unapproved use of an approved medical product in certain situations. With this EUA authority, FDA can help ensure that medical countermeasures may be used in emergencies to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by biological, chemical, nuclear, or radiological agents when there are no adequate, approved, and available alternatives (among other criteria).

II. Criteria for EUA Authorization

Section 564(b)(1) of the FD&C Act provides that, before an EUA may be issued, the Secretary of HHS must declare that circumstances exist justifying the authorization based on one of the following grounds: (A) a determination by the Secretary of Homeland Security that there is a domestic emergency, or a significant potential for a domestic emergency,

involving a heightened risk of attack with a biological, chemical, radiological, or nuclear agent or agents (“CBRN”); (B) a determination by the Secretary of Defense that there is a military emergency, or a significant potential for a military emergency, involving a heightened risk to U.S. military forces, including personnel operating under the authority of title 10 or title 50, U.S. Code, of attack with (i) a CBRN; or (ii) an agent or agents that may cause, or are otherwise associated with, an imminently life-threatening and specific risk to U.S. military forces;¹ (C) a determination by the Secretary of HHS that there is a public health emergency, or a significant potential for a public health emergency, that affects, or has a significant potential to affect, national security or the health and security of U.S. citizens living abroad, and that involves a CBRN agent or agents, or a disease or condition that may be attributable to such agent or agents; or (D) the identification of a material threat by the Secretary of Homeland Security pursuant to section 319F-2 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6b) sufficient to affect national security or the health and security of U.S. citizens living abroad.

Once the Secretary of HHS has declared that circumstances exist justifying an authorization under section 564 of the FD&C Act, FDA may authorize the emergency use of a drug, device, or biological product if the Agency concludes that the statutory criteria are satisfied. Under section 564(h)(1) of the FD&C Act, FDA is required to publish in the **Federal Register** a notice of each authorization, and each termination or revocation of an authorization, and an explanation of the reasons for the action. Under section 564(h)(1) of the FD&C Act, revisions to an authorization shall be made available on FDA’s website. Section 564 of the FD&C Act permits FDA to authorize the introduction into interstate commerce of a drug, device, or biological product intended for use in an actual or potential emergency when the Secretary of HHS has declared that circumstances exist justifying the authorization of emergency use. Products appropriate for emergency use may include products and uses that are not approved, cleared, or licensed under sections 505, 510(k), 512, or 515 of the FD&C Act (21 U.S.C. 355, 360(k), 360b, and 360e) or section

¹ In the case of a determination by the Secretary of Defense, the Secretary of HHS shall determine, within 45 calendar days of such determination, whether to make a declaration under section 564(b)(1) of the FD&C Act, and, if appropriate, shall promptly make such a declaration (see section 564(b)(6) of the FD&C Act).

351 of the PHS Act (42 U.S.C. 262), or conditionally approved under section 571 of the FD&C Act (21 U.S.C. 360ccc).

Under section 564(c) of the FD&C Act, FDA may issue an EUA only if, after consultation with the HHS Assistant Secretary for Preparedness and Response, the Director of the National Institutes of Health, and the Director of the Centers for Disease Control and Prevention (to the extent feasible and appropriate given the applicable circumstances), FDA² concludes: (1) that an agent referred to in a declaration of emergency or threat can cause a serious or life-threatening disease or condition; (2) that, based on the totality of scientific evidence available to FDA, including data from adequate and well-controlled clinical trials, if available, it is reasonable to believe that: (A) the product may be effective in diagnosing, treating, or preventing (i) such disease or condition; or (ii) a serious or life-threatening disease or condition caused by a product authorized under section 564, approved or cleared under the FD&C Act, or licensed under section 351 of the PHS Act, for diagnosing, treating, or preventing such a disease or condition caused by such an agent; and (B) the known and potential benefits of the product, when used to diagnose, prevent, or treat such disease or condition, outweigh the known and potential risks of the product, taking into consideration the material threat posed by the agent or agents identified in a declaration under section 564(b)(1)(D) of the FD&C Act, if applicable; (3) that there is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating such disease or condition; (4) in the case of a determination described in section 564(b)(1)(B)(ii) of the FD&C Act, that the request for emergency use is made by the Secretary of Defense; and (5) that such other criteria as may be prescribed by regulation are satisfied. No other criteria for issuance have been prescribed by regulation under section 564(c)(4) of the FD&C Act.

III. The Authorizations

The Authorizations follow the August 18, 2025, determination by the Secretary of HHS that there is a significant potential for a public health emergency that has a significant potential to affect national security or the health and security of U.S. citizens living abroad and that involves NWS. On the basis of such determination, the Secretary of HHS declared, on August 18, 2025, that

² The Secretary of HHS has delegated the authority to issue an EUA under section 564 of the FD&C Act to the Commissioner of Food and Drugs.

circumstances exist justifying the authorization of emergency use of animal drugs to treat or prevent NWS myiasis in animals. Notice of the Secretary's determination and declaration was provided in the **Federal Register** on August 20, 2025 (90 FR 40609). Having concluded that the criteria for the issuance of the Authorizations under section 564(c) of the FD&C Act are met, FDA has issued four authorizations for the emergency use of animal products. On February 5, 2026, FDA issued an EUA to Boehringer for the animal product Ivomec (ivermectin), subject to the terms of its Authorization. On February 18, 2026, FDA issued two EUAs to Boehringer for

the animal products NexGard (afoxolaner) and NexGard COMBO (esafoxolaner, eprinomectin, and praziquantel topical solution), subject to the terms of their Authorizations. On March 10, 2026, FDA issued an EUA to Health and Hygiene (Pty) Ltd for the animal product F10 Antiseptic Wound Spray with Insecticide (benzalkonium chloride, polyhexanide and cypermethrin topical solution), subject to the terms of its Authorization.

The initial Authorizations, included below in their entirety after section IV of this document (not including the authorized versions of the fact sheets and other written materials), provide explanations of the reasons for issuance,

as required by section 564(h)(1) of the FD&C Act. Any subsequent reissuance of the Authorizations can be found on FDA's web page at: <https://www.fda.gov/animal-veterinary/safety-health/new-world-screwworm-information-veterinarians>.

IV. Electronic Access

An electronic version of this document and the full text of the Authorization is available on the internet at: <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization>.

BILLING CODE 4164-01-P



February 5, 2026

Boehringer Ingelheim Animal Health USA, Inc.
Attention: Tracy Robertson
Regulatory Affairs, Operations
3239 Satellite Blvd.
Duluth, GA 30096

Re: Emergency Use Authorization 006689

Dear Ms. Robertson:

This letter is in response to the request by Boehringer Ingelheim Animal Health USA, Inc. (Boehringer) that the Food and Drug Administration (FDA) issue an Emergency Use Authorization (EUA) for the emergency use of Ivomec (ivermectin) injection for prevention of infestations caused by New World screwworm (*Cochliomyia hominivorax*) larvae (myiasis) when administered within 24 hours of birth, at the time of castration, or at the appearance of a wound in cattle, except for female dairy cattle producing milk for human consumption and calves that will be processed for veal¹, pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 360bbb-3).

On August 18, 2025, pursuant to Section 564(b)(1)(C) of the FD&C Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a significant potential for a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad and that involves New World screwworm (*Cochliomyia hominivorax*) (hereinafter "NWS"). On the basis of such determination, the Secretary of HHS on August 18, 2025, declared that circumstances exist justifying the authorization of emergency use of animal drugs to treat or prevent NWS myiasis in animals, pursuant to section 564(b)(1) of the FD&C Act, subject to terms of any authorization issued under that section.²

Ivomec (ivermectin) injection is an antiparasitic drug that is indicated under NADA 128-409 for the treatment and control of a variety of internal and external parasites in cattle. Ivomec (ivermectin) injection is not approved or conditionally approved for prevention of NWS myiasis.

Based on the scientific evidence available to the FDA, including summaries of dose confirmation studies and published scientific literature, it is reasonable to believe that Ivomec (ivermectin) injection may be effective for prevention of infestations caused by NWS larvae (myiasis) when administered within 24 hours of birth, at the time of castration, or at the appearance of a wound in certain cattle, as described in this authorization, and when used under the conditions described in this authorization, the known and potential benefits of Ivomec (ivermectin) injection

¹ Hereinafter, "cattle, except for female dairy cattle producing milk for human consumption and calves that will be processed for veal," will be referred to as "certain cattle."

² See U.S. Department of Health and Human Services, Declaration of Emergency Pursuant to the Federal Food, Drug, and Cosmetic Act for New World Screwworm, August 20, 2025: <https://www.federalregister.gov/documents/2025/08/20/2025-15918/declaration-of-emergency-pursuant-to-the-federal-food-drug-and-cosmetic-act-for-new-world-screwworm>

Boehringer Ingelheim Animal Health USA, Inc.
Page 2
EUA 006689

outweigh the known and potential risks of such product.

Having concluded that the criteria for issuance of this authorization under Section 564(c) of the FD&C Act are met, I am authorizing the emergency use of Ivomec (ivermectin) injection for prevention of infestations caused by NWS larvae (myiasis) when administered within 24 hours of birth, at the time of castration, or at the appearance of a wound in certain cattle, as described in this authorization and subject to the terms of this authorization.

I. Criteria for Issuance of Authorization

I have concluded that the emergency use of Ivomec (ivermectin) injection for prevention of infestations caused by NWS larvae (myiasis) when administered within 24 hours of birth, at the time of castration, or at the appearance of a wound in certain cattle, when administered as described in this authorization, meets the criteria for issuance of an authorization under Section 564(c) of the FD&C Act, because:

1. NWS can cause a serious or life-threatening disease or condition to animals and humans;
2. Based on the scientific evidence available to FDA, it is reasonable to believe that Ivomec (ivermectin) injection may be effective in preventing NWS, and that, when used under the conditions and within the scope described in this authorization, the known and potential benefits of Ivomec (ivermectin) injection when used to prevent NWS outweigh the known and potential risks of such product; and
3. There is no adequate, approved, and available alternative³ to the emergency use of Ivomec (ivermectin) injection for prevention of infestations caused by NWS larvae (myiasis) in certain cattle for the authorized indications.⁴

II. Scope of Authorization

I have concluded, pursuant to Section 564(d)(1) of the FD&C Act, that the scope of this authorization is limited as follows:

- Ivomec (ivermectin) injection, as covered by this authorization, will be used only for prevention of infestations caused by NWS larvae (myiasis) when administered within 24 hours of birth, at the time of castration, or at the appearance of a wound in certain cattle; and

³ Other therapeutics are conditionally approved for prevention of infestations caused by NWS larvae (myiasis) in cattle. However, these products are not available alternatives because there are insufficient quantities to meet the demands of a widescale incursion of NWS into the United States. In addition, one conditionally approved product is not an adequate alternative because it requires a prescription, potentially delaying administration. There is a significant benefit to expedient administration of a preventative product, particularly if animals nearby are infested. Thus, FDA concluded that this additional OTC injectable macrocyclic lactone product indicated for prevention of NWS in cattle is needed to meet the demands of a widescale incursion of NWS into the United States.

⁴ No other criteria of issuance have been prescribed by regulation under Section 564(c)(4) of the FD&C Act.

- The use of Ivomec (ivermectin) injection covered by this authorization must be in accordance with the authorized Fact Sheet.

Product Description

Ivomec (ivermectin) injection is derived from the avermectins, a family of broad-spectrum antiparasitic agents. The authorized Ivomec (ivermectin) injection carton label is clearly marked for the approved indications and for NWS under Emergency Use Authorization, with a website address and QR code that links to the authorized Fact Sheet.

Store at or below 25°C (77°F) with excursions permitted up to 30°C (86°F). Protect product from light.

Ivomec (ivermectin) injection is authorized to be accompanied by the following product-specific information pertaining to emergency use, which is required to be made available to all users:

- Fact Sheet: Emergency Use Authorization of Ivomec (ivermectin) Injection for New World Screwworm (NWS)

I have concluded, pursuant to Section 564(d)(2) of the FD&C Act, that it is reasonable to believe that the known and potential benefits of Ivomec (ivermectin) injection, when used for prevention of infestations caused by NWS larvae (myiasis) when administered within 24 hours of birth, at the time of castration, or at the appearance of a wound in certain cattle and used in accordance with this authorization, outweigh its known and potential risks.

I have concluded, pursuant to Section 564(d)(3) of the FD&C Act, based on the scientific evidence available to FDA, that it is reasonable to believe that Ivomec (ivermectin) injection may be effective for prevention of infestations caused by NWS larvae (myiasis) when administered within 24 hours of birth, at the time of castration, or at the appearance of a wound in certain cattle when used in accordance with this authorization, pursuant to Section 564(c)(2)(A) of the FD&C Act.

Having reviewed the scientific information available to FDA, including the information supporting the conclusions described in Section I above, I have concluded that Ivomec (ivermectin) injection, as described in this authorization, meets the criteria set forth in Section 564(c) of the FD&C Act concerning safety and potential effectiveness.

The emergency use of this product under an EUA must be consistent with, and may not exceed, the terms of this authorization, including the Scope of Authorization (Section II) and the Conditions of Authorization (Section III). Subject to the terms of this EUA and under the circumstances set forth in the Secretary of HHS's determination under Section 564(b)(1)(C) of the FD&C Act described above and the Secretary of HHS's corresponding declaration under Section 564(b)(1) of the FD&C Act, Ivomec (ivermectin) injection is authorized for prevention of infestations caused by NWS larvae (myiasis) when administered within 24 hours of birth, at the time of castration, or at the appearance of a wound in certain cattle as described in this

Boehringer Ingelheim Animal Health USA, Inc.
Page 4
EUA 006689

authorization, despite the fact that it does not meet certain requirements otherwise required by applicable federal law.

III. Conditions of Authorization

Pursuant to Section 564 of the FD&C Act, I am establishing the following conditions on this authorization:

- A. Boehringer will ensure that the authorized Ivomec (ivermectin) injection, accompanied with the authorized Fact Sheet, is distributed to authorized distributor(s)⁵ consistent with the terms and conditions of this EUA, and that authorized distributor(s) will limit distribution to other authorized distributors and end users.
- B. Boehringer will ensure that if a sticker is used on the labeling, that the sticker contains a website address and QR code that link to the authorized Fact Sheet and that the sticker is placed in a blank space or does not obscure any important use or safety information.
- C. Boehringer and authorized distributor(s) will ensure that appropriate storage conditions are maintained until the product is delivered to the end user.
- D. Boehringer and authorized distributor(s) will provide to each authorized distributor immediately downstream in the supply chain a copy of this Letter of Authorization and promptly communicate any subsequent amendments that might be made to this Letter of Authorization and its authorized accompanying materials (e.g., its authorized Fact Sheet).
- E. Boehringer may request changes to this authorization, including to the authorized Fact Sheet for Ivomec (ivermectin) injection. Requests for changes must be submitted to the Office of New Animal Product Evaluation. Such changes require appropriate authorization prior to implementation.⁶
- F. Reporting Adverse Drug Experiences and Product/Manufacturing Defects:

Boehringer will fully comply with the reporting requirements under 21 CFR 514.80. When collecting adverse event information, Boehringer will attempt to determine whether the use of Ivomec (ivermectin) injection was related to the EUA and will put this categorization, as well as the reason for use, in the narrative description of the adverse event. Boehringer will submit the reports electronically using either of the options that are described on FDA's Veterinary Adverse Event Reporting for Manufacturers webpage (www.fda.gov/IndustryReportAnimalAE).

⁵ The term "distributors" includes all parties in the supply chain between the recipient of this authorization letter and the end user. "Authorized distributors" are all distributors who otherwise lawfully obtain and distribute the product, unless Boehringer places limits on distribution in writing (e.g., via contract or written notice accompanying the product).

⁶ Revisions that do not necessitate revision to this letter (e.g., changes to the Fact Sheet, specified cGMPs, expiration dating extensions) may be authorized through separate notification without reissuance of this letter.

Boehringer Ingelheim Animal Health USA, Inc.
Page 5
EUA 006689

Submitted reports must state in the "Narrative of Adverse Event" field: "Ivomec use for NWS under an EUA". Contact the Pharmacovigilance Liaison in CVM's Division of Pharmacovigilance and Surveillance at CVMAESupport@fda.hhs.gov for any questions related to electronic reporting or for assistance with setting up a Safety Reporting Portal account.

- G. Through a process of inventory control, Boehringer and authorized distributor(s) will maintain records regarding distribution of the authorized Ivomec (ivermectin) injection (i.e., lot numbers, quantity, receiving site, receipt date).
- H. Boehringer and authorized distributor(s) will maintain records in connection with this EUA for at least two years following the termination of the declaration or revocation of the authorization, or until notified by HHS or FDA, whichever is sooner, and will make such records available to FDA for inspection upon request.
- I. Boehringer will comply with all other FD&C Act requirements applicable to the approved product, Ivomec (ivermectin) injection, including, but not limited to, requirements related to registration and listing, drug quality, and manufacturing process, facilities, and equipment in accordance with the approved application⁷ unless such requirement is specifically waived or modified for the authorized product in this authorization. Boehringer shall update their drug listing to reflect the EUA, including submission of updated labeling, before commercial distribution of the EUA product begins.

Conditions of Authorization Related to Advertisements and other Promotional Descriptive Printed Matter

- J. All advertisements (including printed and nonprinted communications) and other promotional descriptive printed matter, relating to the authorized use of Ivomec (ivermectin) injection, shall be consistent with the authorized Fact Sheet⁸, and the terms set forth in this EUA, as well as comply with FD&C Act section 502(a) and 502(n), and 21 CFR Part 202. Additionally, the sponsor and authorized distributor(s) shall comply with any other applicable requirements in the FD&C Act and its implementing regulations regarding advertising and/or promotion.
- K. Boehringer and authorized distributor(s) may not imply that Ivomec (ivermectin) injection is FDA approved or conditionally approved for the authorized use by making statements such as "Ivomec (ivermectin) injection is safe and effective for prevention of infestations caused by NWS (*Cochliomyia hominivorax*) larvae (myiasis) when administered within 24 hours of birth, at the time of castration, or at the appearance of a wound in certain cattle". Boehringer and authorized distributor(s) may disseminate advertisements (including printed and nonprinted communications) and other promotional descriptive printed matter relating to the emergency use of Ivomec (ivermectin) injection that provide accurate descriptions of safety and

⁷ Changes shall be submitted and approved in accordance with 21 CFR 514.8, unless otherwise approved under Paragraph E of this letter.

⁸ If the authorized Fact Sheet references sections of a drug's FDA-approved labeling, the entirety of each section is considered part of the Fact Sheet, except as otherwise specified. Advertising and promotional materials may not use general references to approved labeling in lieu of summarizing or restating its contents when a summary or restatement is otherwise needed to comply with applicable requirements.

Boehringer Ingelheim Animal Health USA, Inc.
Page 6
EUA 006689

effectiveness information summarized in the authorized Fact Sheet. Such materials must include any limitations of information submitted to support this authorization.

- L. All advertisements (including printed and nonprinted communications) and other promotional descriptive printed matter relating to the authorized use of Ivomec (ivermectin) injection shall be accompanied by the authorized Fact Sheet and the applicable approved labeling (e.g., package insert), and shall clearly and conspicuously state that:
- Ivomec (ivermectin) injection has not been approved for prevention of infestations caused by NWS (*Cochliomyia hominivorax*) larvae (myiasis) when administered within 24 hours of birth, at the time of castration, or at the appearance of a wound in certain cattle;
 - Ivomec (ivermectin) injection has been authorized by FDA under an EUA for prevention of infestations caused by NWS (*Cochliomyia hominivorax*) larvae (myiasis) when administered within 24 hours of birth, at the time of castration, or at the appearance of a wound in certain cattle; and
 - Ivomec (ivermectin) injection is authorized as described herein only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Ivomec (ivermectin) injection under Section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revised or revoked sooner.
- M. All advertisements (including printed and nonprinted communications) and other promotional descriptive printed matter must be submitted to the CVM OSC DER eSubmitter Program at the time of initial dissemination (publication or broadcast). Each submission of promotional labeling or advertisements must be accompanied by a completed Form FDA 2301.

If FDA notifies Boehringer that any descriptive materials, advertising, or promotional materials do not meet the terms set forth in this EUA, Boehringer must discontinue and/or cease distribution of such advertisements (including printed and nonprinted communications) and other promotional descriptive printed matter in accordance with FDA's notification. Furthermore, as part of its notification, FDA may also require Boehringer to issue corrective communication(s).

Boehringer Ingelheim Animal Health USA, Inc.
Page 7
EUA 006689

IV. Duration of Authorization

This EUA will be effective as described herein until the declaration that circumstances exist justifying the authorization of the emergency use of animal drugs during the NWS public health emergency is terminated under Section 564(b)(2) of the FD&C Act or the EUA is revised or revoked under Section 564(g) of the FD&C Act.

Sincerely,

{see appended electronic signature page}

Timothy Schell, Ph.D.
Director
Center for Veterinary Medicine
U.S. Food and Drug Administration

Enclosures:
Freedom of Information Summary
Fact Sheet



February 18, 2026

Boehringer Ingelheim Animal Health USA, Inc.
Attention: Tracy L. Robertson
Regulatory Affairs, Operations
3239 Satellite Blvd.
Duluth, GA 30096

Re: Emergency Use Authorization 006685

Dear Ms. Robertson:

This letter is in response to the request by Boehringer Ingelheim Animal Health USA, Inc. (Boehringer) that the Food and Drug Administration (FDA) issue an Emergency Use Authorization (EUA) for the emergency use of NexGard (afoxolaner) chewables for the treatment of infestations caused by New World screwworm (*Cochliomyia hominivorax*) larvae (myiasis) in dogs and puppies, pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 360bbb-3).

On August 18, 2025, pursuant to Section 564(b)(1)(C) of the FD&C Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is significant potential for a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad and that involves New World screwworm (*Cochliomyia hominivorax*) (hereinafter "NWS"). On the basis of such determination, the Secretary of HHS on August 18, 2025 declared that circumstances exist justifying the authorization of emergency use of animal drugs to treat or prevent NWS myiasis in animals, pursuant to section 564(b)(1) of the FD&C Act, subject to terms of any authorization issued under that section.¹

NexGard is an antiparasitic. NexGard kills fleas and is indicated under NADA 141-406 for the treatment and prevention of flea infestations (*Ctenocephalides felis*), and the treatment and control of *Ixodes scapularis* (black-legged tick), *Dermacentor variabilis* (American dog tick), *Amblyomma americanum* (lone star tick), *Rhipicephalus sanguineus* (brown dog tick), and *Haemaphysalis longicornis* (longhorned tick) infestations in dogs and puppies 8 weeks of age and older, weighing 4 pounds of body weight or greater, for one month. NexGard is also indicated under NADA 141-406 for the prevention of *Borrelia burgdorferi* infections as a direct result of killing *Ixodes scapularis* vector ticks. NexGard is not approved for the treatment of NWS myiasis.

Based on the totality of scientific evidence available to the FDA, including data from published scientific literature, it is reasonable to believe that NexGard may be effective for the treatment of infestations caused by NWS larvae (myiasis) in dogs and puppies, as described in this authorization, and when used under the conditions described in this authorization, the known

¹ See U.S. Department of Health and Human Services, Declaration of Emergency Pursuant to the Federal Food, Drug, and Cosmetic Act for New World Screwworm, August 20, 2025: <https://www.federalregister.gov/documents/2025/08/20/2025-15918/declaration-of-emergency-pursuant-to-the-federal-food-drug-and-cosmetic-act-for-new-world-screwworm>

and potential benefits of NexGard outweigh the known and potential risks of such product for dogs of all ages and weights because NWS is potentially fatal in dogs if left untreated, therefore justifying including dogs less than 8 weeks of age or less than 4 pounds in this authorization.

Having concluded that the criteria for issuance of this authorization under Section 564(c) of the FD&C Act are met, I am authorizing the emergency use of NexGard for the treatment of infestations caused by NWS larvae (myiasis) in dogs and puppies, as described in this authorization and subject to the terms of this authorization.

I. Criteria for Issuance of Authorization

I have concluded that the emergency use of NexGard for the treatment of infestations caused by NWS larvae (myiasis) in dogs and puppies, when administered as described in this authorization, meets the criteria for issuance of an authorization under Section 564(c) of the FD&C Act, because:

1. NWS can cause a serious or life-threatening disease or condition to animals and humans;
2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe that NexGard may be effective in treating NWS and that, when used under the conditions and within the scope described in this authorization, the known and potential benefits of NexGard when used to treat NWS outweigh the known and potential risks of such product; and
3. There is no adequate, approved, and available alternative² to the emergency use of NexGard for the treatment of infestations caused by NWS larvae (myiasis) in dogs and puppies.³

II. Scope of Authorization

I have concluded, pursuant to Section 564(d)(1) of the FD&C Act, that the scope of this authorization is limited as follows:

- NexGard, as covered by this authorization, will be used only for the treatment of infestations caused by NWS larvae (myiasis) in dogs and puppies by a veterinarian by prescription; and
- The use of NexGard covered by this authorization must be in accordance with the authorized Fact Sheet.

² There are no approved alternatives for dogs and puppies under 8 weeks of age or weighing less than 3.3 pounds because the conditionally approved product is approved to treat NWS in dogs and puppies at least 8 weeks of age and weighing at least 3.3 pounds. Additionally, there are no adequate approved alternative products containing a single active ingredient. The conditionally approved product contains multiple active ingredients, use of which may increase the likelihood of adverse events in dogs recently treated with a heartworm preventative or other antiparasitic drug in the same class as one of the ingredients in the conditionally approved product. Therefore, NexGard containing only a single active ingredient may minimize the potential for adverse events in these dogs.

³ No other criteria of issuance have been prescribed by regulation under Section 564(c)(4) of the FD&C Act.

Boehringer Ingelheim Animal Health USA, Inc.
Page 3
EUA 006685

Product Description

NexGard is an antiparasitic. The authorized NexGard carton labeling is clearly marked for the approved indications and for NWS under Emergency Use Authorization, with a website address and QR code that links to the authorized Fact Sheet.

Store at or below 30°C (86°F), excursions permitted up to 40°C (104°F).

NexGard is authorized to be accompanied by the following product-specific information pertaining to emergency use, which is required to be made available to veterinarians and others who may administer the product:

- Fact Sheet for Veterinarians: Emergency Use Authorization of NexGard (afoxolaner) Chewables for New World Screwworm (NWS)

I have concluded, pursuant to Section 564(d)(2) of the FD&C Act, that it is reasonable to believe that the known and potential benefits of NexGard, when used for the treatment of infestations caused by NWS larvae (myiasis) in dogs and puppies and used in accordance with this authorization, outweigh its known and potential risks.

I have concluded, pursuant to Section 564(d)(3) of the FD&C Act, based on the totality of scientific evidence available to FDA, that it is reasonable to believe that NexGard may be effective for the treatment of infestations caused by NWS larvae (myiasis) in dogs and puppies when used in accordance with this authorization, pursuant to Section 564(c)(2)(A) of the FD&C Act.

Having reviewed the scientific information available to FDA, including the information supporting the conclusions described in Section I above, I have concluded that NexGard, as described in this authorization, meets the criteria set forth in Section 564(c) of the FD&C Act concerning safety and potential effectiveness.

The emergency use of this product under an EUA must be consistent with, and may not exceed, the terms of this authorization, including the Scope of Authorization (Section II) and the Conditions of Authorization (Section III). Subject to the terms of this EUA and under the circumstances set forth in the Secretary of HHS's determination under Section 564(b)(1)(C) of the FD&C Act described above and the Secretary of HHS's corresponding declaration under Section 564(b)(1) of the FD&C Act, NexGard is authorized for the treatment of infestations caused by NWS larvae (myiasis) in dogs and puppies as described in the this authorization, despite the fact that it does not meet certain requirements otherwise required by applicable federal law.

III. Conditions of Authorization

Pursuant to Section 564 of the FD&C Act, I am establishing the following conditions on this authorization:

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20903
www.fda.gov

Boehringer Ingelheim Animal Health USA, Inc.
Page 4
EUA 006685

- A. Boehringer will ensure that the authorized NexGard, accompanied with the authorized Fact Sheet, is distributed to veterinary facilities⁴ and veterinarians, or authorized distributor(s)⁵, consistent with the terms and conditions of this EUA, and that authorized distributor(s) will limit distribution to other authorized distributors and end users.
- B. Boehringer will ensure that if a sticker is used on the labeling, that the sticker contains a website address and QR code that link to the authorized Fact Sheet and that the sticker is placed in a blank space or does not obscure any important use or safety information.
- C. Boehringer and authorized distributor(s) will ensure that appropriate storage is maintained until the product is delivered to veterinary facilities and veterinarians.
- D. Boehringer and authorized distributor(s) will ensure that the terms and conditions of this EUA are made available to all relevant stakeholders (e.g., U.S. government agencies, state and local government authorities, authorized distributors, veterinary facilities, and veterinarians) involved in distributing or receiving authorized NexGard. Boehringer will provide to all relevant stakeholders a copy of this Letter of Authorization and communicate any subsequent amendments that might be made to this Letter of Authorization and its authorized accompanying materials (e.g., its authorized Fact Sheet).
- E. Boehringer may request changes to this authorization, including to the authorized Fact Sheet for NexGard. Requests for changes should be submitted to the Office of New Animal Product Evaluation. Such changes require appropriate authorization prior to implementation.⁶
- F. Reporting Adverse Drug Experiences and Product/Manufacturing Defects:

Boehringer will fully comply with the reporting requirements under 21 CFR 514.80. When collecting adverse event information, Boehringer will attempt to determine whether the use of NexGard was related to the EUA and will put this categorization, as well as the reason for use, in the narrative description of the adverse event. Boehringer will submit the reports electronically using either of the options that are described on FDA's Veterinary Adverse Event Reporting for Manufacturers webpage (www.fda.gov/IndustryReportAnimalAE).

Submitted reports should state in the "Narrative of Adverse Event" field: "NexGard use for NWS under an EUA". Contact the Pharmacovigilance Liaison in CVM's Division of Pharmacovigilance and Surveillance at CVMAESupport@fda.hhs.gov for any questions related to electronic reporting or for assistance with setting up a Safety Reporting Portal account.

⁴ Veterinary facilities include veterinary hospitals, veterinary clinics and other establishments providing veterinary care. If a veterinarian is not associated with a veterinary facility, the veterinarian then assumes the obligations of the veterinary facility.

⁵ The term "distributors" includes all parties in the supply chain between the recipient of this authorization letter and the end user. "Authorized distributors" are all distributors who otherwise lawfully obtain and distribute the product, unless Boehringer places limits on distribution in writing (e.g., via contract or written notice accompanying the product).

⁶ Revisions that do not necessitate revision to this letter (e.g., changes to the Fact Sheet, specified cGMPs, expiration dating extensions) may be authorized through separate notification without reissuance of this letter.

Boehringer Ingelheim Animal Health USA, Inc.
Page 5
EUA 006685

- G. Through a process of inventory control, Boehringer and authorized distributor(s) will maintain records regarding distribution of the authorized NexGard (i.e., lot numbers, quantity, receiving site, receipt date).
- H. Boehringer and authorized distributor(s) will maintain records in connection with this EUA for at least two years following the termination of the declaration or the revocation of the authorization, or until notified by HHS or FDA, whichever is sooner, and will make such records available to FDA for inspection upon request.
- I. Boehringer will comply with all other FD&C Act requirements applicable to the approved product, NexGard, including, but not limited to, requirements related to registration and listing, drug quality, and manufacturing process, facilities, and equipment in accordance with the approved application⁷, unless such requirement is specifically waived or modified for the authorized product in this authorization. Boehringer shall update their drug listing to reflect the EUA, including submission of updated labeling, before commercial distribution of the EUA product begins.

Conditions of Authorization for Veterinary Facilities and Veterinarians

- J. Veterinary facilities and veterinarians will ensure that they are aware of and adhere to the terms of this Letter of Authorization. Authorized Fact Sheets will be made available to veterinarians, and veterinary facilities and veterinarians will ensure that the client is aware that the drug is authorized for emergency use, but not approved, for the treatment of NWS myiasis and advise the client of the risks, benefits, and any alternatives.
- K. Veterinary facilities and veterinarians receiving NexGard will track serious adverse events potentially related to NexGard use under this EUA and must report these to FDA in accordance with the Fact Sheet for Veterinarians. Report by (1) contacting Boehringer at 1-888-637-4251, (2) downloading and submitting Form FDA 1932a available at <https://www.fda.gov/reportanimalae>, or (3) contacting FDA at 1-888-FDA-VETS to request this form. Include the statement "NexGard use for NWS under an EUA" under the "Describe Adverse Event/Product Problem/Product Use Error" heading, followed by a detailed account of the adverse event.
- L. Veterinary facilities will maintain health records that include the following information: client name, patient name, patient age, disease manifestation, number of doses prescribed or administered per patient, lot number prescribed or administered, and other drugs coadministered. The records shall be maintained in a manner that allows veterinary facilities to identify in a reasonable time which patients received drugs subject to this EUA.
- M. Veterinary facilities will maintain any records associated with this EUA for at least two years following the termination of the declaration or the revocation of the authorization, or until notified by HHS or FDA, whichever is sooner. Such records will be made available to Boehringer, HHS, and FDA for inspection upon request.

⁷ Changes shall be submitted and approved in accordance with 21 CFR 514.8, unless otherwise approved under Paragraph E of this letter.

Conditions of Authorization Related to Advertisements and other Promotional Descriptive Printed Matter

- N. All advertisements (including printed and nonprinted communications) and other promotional descriptive printed matter, relating to the authorized use of NexGard shall be consistent with the authorized Fact Sheet⁹, and the terms set forth in this EUA, as well as comply with FD&C Act sections 502(a) and 502(n), and 21 CFR Part 202. Additionally, the sponsor and authorized distributor(s) shall comply with any other applicable requirements in the FD&C Act and its implementing regulations regarding advertising and/or promotion.
- O. Boehringer and authorized distributor(s) may not imply that NexGard is FDA approved or conditionally approved for the authorized use by making statements such as "NexGard is safe and effective for the treatment of infestations caused by NWS larvae (myiasis) in dogs and puppies". Boehringer and authorized distributor(s) may disseminate advertisements (including printed and nonprinted communications) and other promotional descriptive printed matter relating to the emergency use of NexGard that provide accurate descriptions of safety and effectiveness information summarized in the authorized Fact Sheet. Such materials must include any limitations of information submitted to support this authorization.
- P. All advertisements (including printed and nonprinted communications) and other promotional descriptive printed matter relating to the authorized use of NexGard shall be accompanied by the authorized Fact Sheet and the applicable approved labeling (e.g., package insert), and shall clearly and conspicuously state that:
- NexGard has not been approved for the treatment of infestations caused by NWS larvae (myiasis) in dogs and puppies;
 - NexGard has been authorized by FDA under an EUA for the treatment of infestations caused by NWS larvae (myiasis) in dogs and puppies; and
 - NexGard is authorized as described herein only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of NexGard under Section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or the authorization is revised or revoked sooner.
- Q. All advertisements (including printed and nonprinted communications) and other promotional descriptive printed matter must be submitted to the CVM OSC DER eSubmitter Program at the time of initial dissemination (publication or broadcast). Each submission of promotional labeling or advertisements must be accompanied by a completed Form FDA 2301.

If FDA notifies Boehringer or authorized distributor(s) that any descriptive materials, advertising, or promotional materials do not meet the terms set forth in this EUA, Boehringer

⁹ If the authorized Fact Sheet references sections of a drug's FDA-approved labeling, the entirety of each section is considered part of the authorized Fact Sheet, except as otherwise specified. Advertising and promotional materials may not use general references to approved labeling in lieu of summarizing or restating its contents when a summary or restatement is otherwise needed to comply with applicable requirements.

Boehringer Ingelheim Animal Health USA, Inc.
Page 7
EUA 006685

or authorized distributor(s) must discontinue and/or cease distribution of such advertisements (including printed and nonprinted communications) and other promotional descriptive printed matter in accordance with FDA's notification. Furthermore, as part of its notification, FDA may also require Boehringer or authorized distributor(s) to issue corrective communication(s).

IV. Duration of Authorization

This EUA will be effective as described herein until the declaration that circumstances exist justifying the authorization of the emergency use of animal drugs during the NWS public health emergency is terminated under Section 564(b)(2) of the FD&C Act or the EUA is revised or revoked under Section 564(g) of the FD&C Act.

Sincerely,

{see appended electronic signature page}

Timothy Schell, Ph.D.
Director
Center for Veterinary Medicine
U.S. Food and Drug Administration

Enclosures:
Freedom of Information Summary
Fact Sheet



February 18, 2026

Boehringer Ingelheim Animal Health USA, Inc.
Attention: Tracy L. Robertson
Regulatory Affairs, Operations
3239 Satellite Blvd.
Duluth, GA 30096

Re: Emergency Use Authorization 006686

Dear Ms. Robertson:

This letter is in response to the request by Boehringer Ingelheim Animal Health USA, Inc. (Boehringer) that the Food and Drug Administration (FDA) issue an Emergency Use Authorization (EUA) for the emergency use of NexGard COMBO (esafoxolaner, eprinomectin, and praziquantel topical solution) for the treatment of infestations caused by New World screwworm (*Cochliomyia hominivorax*) larvae (myiasis) in cats and kittens, pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 360bbb-3).

On August 18, 2025, pursuant to Section 564(b)(1)(C) of the FD&C Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is significant potential for a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad and that involves New World screwworm (*Cochliomyia hominivorax*) (hereinafter "NWS"). On the basis of such determination, the Secretary of HHS on August 18, 2025 declared that circumstances exist justifying the authorization of emergency use of animal drugs to treat or prevent NWS myiasis in animals, pursuant to section 564(b)(1) of the FD&C Act, subject to terms of any authorization issued under that section.¹

NexGard COMBO is a topical antiparasitic that is indicated under NADA 141-570 for the prevention of heartworm disease caused by *Dirofilaria immitis* and for the treatment and control of roundworm (fourth stage larval and adult *Toxocara cati*), hookworm (fourth stage larval and adult *Ancylostoma tubaeforme*; adult *Ancylostoma braziliense*), and tapeworm (*Dipylidium caninum*) infections. NexGard COMBO kills adult fleas (*Ctenocephalides felis*) and is also indicated under NADA 141-570 for the treatment and prevention of flea infestations and the treatment and control of *Ixodes scapularis* (black-legged tick) and *Amblyomma americanum* (lone star tick) infestations for one month in cats and kittens 8 weeks of age and older, and weighing 1.8 lbs or greater. NexGard COMBO is not approved for the treatment of NWS larvae (myiasis).

Based on the totality of scientific evidence available to the FDA, including data from a laboratory effectiveness study, it is reasonable to believe that NexGard COMBO may be effective for the treatment of infestations caused NWS larvae (myiasis) in cats and kittens, as described in this

¹ See U.S. Department of Health and Human Services, Declaration of Emergency Pursuant to the Federal Food, Drug, and Cosmetic Act for New World Screwworm, August 20, 2025: <https://www.federalregister.gov/documents/2025/08/20/2025-15918/declaration-of-emergency-pursuant-to-the-federal-food-drug-and-cosmetic-act-for-new-world-screwworm>

Boehringer Ingelheim Animal Health USA, Inc.
Page 2
EUA 006686

authorization, and when used under the conditions described in this authorization, the known and potential benefits of NexGard COMBO outweigh the known and potential risks of such product for cats of all ages and weights because NWS is potentially fatal in cats if left untreated, therefore justifying including cats less than 8 weeks of age and less than 1.8 lbs in this authorization.

Having concluded that the criteria for issuance of this authorization under Section 564(c) of the FD&C Act are met, I am authorizing the emergency use of NexGard COMBO for the treatment of infestations caused by NWS larvae (myiasis) in cats and kittens, as described in this authorization and subject to the terms of this authorization.

I. Criteria for Issuance of Authorization

I have concluded that the emergency use of NexGard COMBO for the treatment of infestations caused by NWS larvae (myiasis) in cats and kittens, when administered as described in this authorization, meets the criteria for issuance of an authorization under Section 564(c) of the FD&C Act, because:

1. NWS can cause a serious or life-threatening disease or condition to animals and humans;
2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe that NexGard COMBO may be effective in treating NWS and that, when used under the conditions and within the scope described in this authorization, the known and potential benefits of NexGard COMBO when used to treat NWS outweigh the known and potential risks of such product; and
3. There is no adequate, approved, and available alternative² to the emergency use of NexGard COMBO for the treatment of infestations caused by NWS larvae (myiasis) in cats and kittens.³

II. Scope of Authorization

I have concluded, pursuant to Section 564(d)(1) of the FD&C Act, that the scope of this authorization is limited as follows:

- NexGard COMBO, as covered by this authorization, will be used only for the treatment of infestations caused by NWS larvae (myiasis) in cats and kittens by a veterinarian by prescription; and
- The use of NexGard COMBO covered by this authorization must be in accordance with the authorized Fact Sheet.

² There are no approved products for the treatment of New World screwworm (myiasis) in cats and kittens.

³ No other criteria of issuance have been prescribed by regulation under Section 564(c)(4) of the FD&C Act.

Product Description

NexGard COMBO is a topical antiparasitic. The authorized NexGard COMBO carton labeling is clearly marked for the approved indications and for NWS under Emergency Use Authorization, with a website address and QR code that links to the authorized Fact Sheet.

NexGard COMBO should be stored at 59° – 86°F (15° – 30°C). Brief periods up to 104°F (40°C) are permitted. Protect from light.

NexGard COMBO is authorized to be accompanied by the following product-specific information pertaining to emergency use, which is required to be made available to veterinarians and others who may administer the product:

- Fact Sheet for Veterinarians: Emergency Use Authorization of NexGard COMBO (esafoxolaner, eprinomectin, and praziquantel topical solution) for New World Screwworm (NWS).

I have concluded, pursuant to Section 564(d)(2) of the FD&C Act, that it is reasonable to believe that the known and potential benefits of NexGard COMBO, when used for the treatment of infestations caused by NWS larvae (myiasis) in cats and kittens and used in accordance with this authorization, outweigh its known and potential risks.

I have concluded, pursuant to Section 564(d)(3) of the FD&C Act, based on the totality of scientific evidence available to FDA, that it is reasonable to believe that NexGard COMBO may be effective for the treatment of infestations caused by NWS larvae (myiasis) in cats and kittens when used in accordance with this authorization, pursuant to Section 564(c)(2)(A) of the FD&C Act.

Having reviewed the scientific information available to FDA, including the information supporting the conclusions described in Section I above, I have concluded that NexGard COMBO, as described in this authorization, meets the criteria set forth in Section 564(c) of the FD&C Act concerning safety and potential effectiveness.

The emergency use of this product under an EUA must be consistent with, and may not exceed, the terms of this authorization, including the Scope of Authorization (Section II) and the Conditions of Authorization (Section III). Subject to the terms of this EUA and under the circumstances set forth in the Secretary of HHS's determination under Section 564(b)(1)(C) of the FD&C Act described above and the Secretary of HHS's corresponding declaration under Section 564(b)(1) of the FD&C Act, NexGard COMBO is authorized for the treatment of infestations caused by NWS larvae (myiasis) in cats and kittens as described in this authorization, despite the fact that it does not meet certain requirements otherwise required by applicable federal law.

III. Conditions of Authorization

Pursuant to Section 564 of the FD&C Act, I am establishing the following conditions on this authorization:

Boehringer Ingelheim Animal Health USA, Inc.
Page 4
EUA 006686

- A. Boehringer will ensure that the authorized NexGard COMBO, accompanied with the authorized Fact Sheet, is distributed to veterinary facilities⁴ and veterinarians, or authorized distributor(s)⁵, consistent with the terms and conditions of this EUA, and that authorized distributor(s) will limit distribution to other authorized distributors and end users.
- B. Boehringer will ensure that if a sticker is used on the labeling, that the sticker contains a website address and QR code that link to the authorized Fact Sheet and that the sticker is placed in a blank space or does not obscure any important use or safety information.
- C. Boehringer and authorized distributor(s) will ensure that appropriate storage is maintained until the product is delivered to veterinary facilities and veterinarians.
- D. Boehringer and authorized distributor(s) will ensure that the terms and conditions of this EUA are made available to all relevant stakeholders (e.g., U.S. government agencies, state and local government authorities, authorized distributors, veterinary facilities, and veterinarians) involved in distributing or receiving authorized NexGard COMBO. Boehringer will provide to all relevant stakeholders a copy of this Letter of Authorization and communicate any subsequent amendments that might be made to this Letter of Authorization and its authorized accompanying materials (e.g., its authorized Fact Sheet).
- E. Boehringer may request changes to this authorization, including to the authorized Fact Sheet for NexGard COMBO. Requests for changes should be submitted to the Office of New Animal Product Evaluation. Such changes require appropriate authorization prior to implementation.⁶
- F. Reporting Adverse Drug Experiences and Product/Manufacturing Defects:

Boehringer will fully comply with the reporting requirements under 21 CFR 514.80. When collecting adverse event information, Boehringer will attempt to determine whether the use of NexGard COMBO was related to the EUA and will put this categorization, as well as the reason for use, in the narrative description of the adverse event. Boehringer will submit the reports electronically using either of the options that are described on FDA's Veterinary Adverse Event Reporting for Manufacturers webpage (www.fda.gov/IndustryReportAnimalAE).

Submitted reports should state in the "Narrative of Adverse Event" field: "NexGard COMBO use for NWS under an EUA". Contact the Pharmacovigilance Liaison in CVM's Division of Pharmacovigilance and Surveillance at CVMAESupport@fda.hhs.gov for any questions

⁴ Veterinary facilities include veterinary hospitals, veterinary clinics and other establishments providing veterinary care. If a veterinarian is not associated with a veterinary facility, the veterinarian then assumes the obligations of the veterinary facility.

⁵ The term "distributors" includes all parties in the supply chain between the recipient of this authorization letter and the end user. "Authorized distributors" are all distributors who otherwise lawfully obtain and distribute the product, unless Boehringer places limits on distribution in writing (e.g., via contract or written notice accompanying the product).

⁶ Revisions that do not necessitate revision to this letter (e.g., changes to the Fact Sheet, specified cGMPs, expiration dating extensions) may be authorized through separate notification without reissuance of this letter.

Boehringer Ingelheim Animal Health USA, Inc.
Page 5
EUA 006686

related to electronic reporting or for assistance with setting up a Safety Reporting Portal account.

- G. Through a process of inventory control, Boehringer and authorized distributor(s) will maintain records regarding distribution of the authorized NexGard COMBO (i.e., lot numbers, quantity, receiving site, receipt date).
- H. Boehringer and authorized distributor(s) will maintain records in connection with this EUA for at least two years following the termination of the declaration or the revocation of the authorization, or until notified by HHS or FDA, whichever is sooner, and will make such records available to FDA for inspection upon request.
- I. Boehringer will comply with all other FD&C Act requirements applicable to the approved product, NexGard COMBO, including, but not limited to, requirements related to registration and listing, drug quality, and manufacturing process, facilities, and equipment in accordance with the approved application⁷, unless such requirement is specifically waived or modified for the authorized product in this authorization. Boehringer shall update their drug listing to reflect the EUA, including submission of updated labeling, before commercial distribution of the EUA product begins.

Conditions of Authorization for Veterinary Facilities and Veterinarians

- J. Veterinary facilities and veterinarians will ensure that they are aware of and adhere to the terms of this Letter of Authorization. Authorized Fact Sheets will be made available to veterinarians, and veterinary facilities and veterinarians will ensure that the client is aware that the drug is authorized for emergency use, but not approved, for the treatment of NWS myiasis and advise the client of the risks, benefits, and any alternatives.
- K. Veterinary facilities and veterinarians receiving NexGard COMBO will track serious adverse events potentially related to NexGard COMBO use under this EUA and must report these to FDA in accordance with the Fact Sheet for Veterinarians. Report by (1) contacting Boehringer at 1-888-637-4251, (2) downloading and submitting Form FDA 1932a available at <https://www.fda.gov/reportanimalae>, or (3) contacting FDA at 1-888-FDA-VETS to request this form. Include the statement "NexGard COMBO use for NWS under an EUA" under the "Describe Adverse Event/Product Problem/Product Use Error" heading, followed by a detailed account of the adverse event.
- L. Veterinary facilities will maintain health records that include the following information: client name, patient name, patient age, disease manifestation, number of doses prescribed or administered per patient, lot number prescribed or administered, and other drugs coadministered. The records shall be maintained in a manner that allows veterinary facilities to identify in a reasonable time which patients received drugs subject to this EUA.
- M. Veterinary facilities will maintain any records associated with this EUA for at least two years following the termination of the declaration or the revocation of the authorization, or until

⁷ Changes shall be submitted and approved in accordance with 21 CFR 514.8, unless otherwise approved under Paragraph E of this letter.

Boehringer Ingelheim Animal Health USA, Inc.
Page 6
EUA 006686

notified by HHS or FDA, whichever is sooner. Such records will be made available to Boehringer, HHS, and FDA for inspection upon request.

Conditions of Authorization Related to Advertisements and other Promotional Descriptive Printed Matter

- N. All advertisements (including printed and nonprinted communications) and other promotional descriptive printed matter, relating to the authorized use of NexGard COMBO shall be consistent with the authorized Fact Sheet⁹, and the terms set forth in this EUA, as well as comply with FD&C Act sections 502(a) and 502(n), and 21 CFR Part 202. Additionally, the sponsor and authorized distributor(s) shall comply with any other applicable requirements in the FD&C Act and its implementing regulations regarding advertising and/or promotion.
- O. Boehringer and authorized distributor(s) may not imply that NexGard COMBO is FDA approved or conditionally approved for the authorized use by making statements such as "NexGard COMBO is safe and effective for the treatment of infestations caused by New World screwworm (*Cochliomyia hominivorax*) larvae (myiasis) in cats and kittens". Boehringer and authorized distributor(s) may disseminate advertisements (including printed and nonprinted communications) and other promotional descriptive printed matter relating to the emergency use of NexGard COMBO that provide accurate descriptions of safety and effectiveness information summarized in the authorized Fact Sheet. Such materials must include any limitations of information submitted to support this authorization.
- P. All advertisements (including printed and nonprinted communications) and other promotional descriptive printed matter relating to the authorized use of NexGard COMBO shall be accompanied by the authorized Fact Sheet and the applicable approved labeling (e.g., package insert), and shall clearly and conspicuously state that:
- NexGard COMBO has not been approved for the treatment of infestations caused by NWS larvae (myiasis) in cats and kittens;
 - NexGard COMBO has been authorized by FDA under an EUA for the treatment of infestations caused by NWS larvae (myiasis) in cats and kittens; and
 - NexGard COMBO is authorized as described herein only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of NexGard COMBO under Section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or the authorization is revised or revoked sooner.
- Q. All advertisements (including printed and nonprinted communications) and other promotional descriptive printed matter must be submitted to the CVM OSC DER eSubmitter Program at the time of initial dissemination (publication or broadcast). Each submission of promotional labeling or advertisements must be accompanied by a completed Form FDA 2301.

⁹ If the authorized Fact Sheet references sections of a drug's FDA-approved labeling, the entirety of each section is considered part of the authorized Fact Sheet, except as otherwise specified. Advertising and promotional materials may not use general references to approved labeling in lieu of summarizing or restating its contents when a summary or restatement is otherwise needed to comply with applicable requirements.

Boehringer Ingelheim Animal Health USA, Inc.

Page 7

EUA 006686

If FDA notifies Boehringer or authorized distributor(s) that any descriptive materials, advertising, or promotional materials do not meet the terms set forth in this EUA, Boehringer or authorized distributor(s) must discontinue and/or cease distribution of such advertisements (including printed and nonprinted communications) and other promotional descriptive printed matter in accordance with FDA's notification. Furthermore, as part of its notification, FDA may also require Boehringer or authorized distributor(s) to issue corrective communication(s).

IV. Duration of Authorization

This EUA will be effective as described herein until the declaration that circumstances exist justifying the authorization of the emergency use of animal drugs during the NWS public health emergency is terminated under Section 564(b)(2) of the FD&C Act or the EUA is revised or revoked under Section 564(g) of the FD&C Act.

Sincerely,

(see appended electronic signature page)

Timothy Schell, Ph.D.

Director

Center for Veterinary Medicine

U.S. Food and Drug Administration

Enclosures:

Freedom of Information Summary

Fact Sheet



March 10, 2026

Animal Clinical Investigation, LLC
Attention: Kristen Khanna, PhD, MBA
CEO
U.S. Agent for Health and Hygiene (Pty) Ltd
4445 Willard Ave
Sixth Floor
Chevy Chase, MD 20815

Re: Emergency Use Authorization 006672

Dear Dr. Khanna:

This letter is in response to the request you submitted on behalf of Health and Hygiene (Pty) Ltd (Health and Hygiene), that the Food and Drug Administration (FDA) issue an Emergency Use Authorization (EUA) for the emergency use of F10 Antiseptic Wound Spray with Insecticide (benzalkonium chloride, polyhexanide and cypermethrin topical solution), for the prevention and treatment of infestations caused by New World screwworm (*Cochliomyia hominivorax*) larvae (myiasis) in cattle, horses, minor species¹ of hoof stock, raptors and other wild birds, pet birds, and captive wild, exotic, and zoo mammals, pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 360bbb-3).

On August 18, 2025, pursuant to Section 564(b)(1)(C) of the FD&C Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a significant potential for a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad and that involves New World screwworm (*Cochliomyia hominivorax*) (hereinafter "NWS"). On the basis of such determination, the Secretary of HHS on August 18, 2025, declared that circumstances exist justifying the authorization of emergency use of animal drugs to treat or prevent NWS myiasis in animals, pursuant to section 564(b)(1) of the FD&C Act, subject to terms of any authorization issued under that section.²

¹ Minor species are all animals, other than humans, that are not one of the major species. They include animals such as zoo animals, parrots, ferrets, and guinea pigs. Some animals of agricultural importance are also minor species. These include sheep, goats, and game birds, among others. The term 'major species' means cattle, horses, swine, chickens, turkeys, dogs, and cats.

² See U.S. Department of Health and Human Services, Declaration of Emergency Pursuant to the Federal Food, Drug, and Cosmetic Act for New World Screwworm, August 20, 2025: <https://www.federalregister.gov/documents/2025/08/20/2025-15918/declaration-of-emergency-pursuant-to-the-federal-food-drug-and-cosmetic-act-for-new-world-screwworm>

F10 Antiseptic Wound Spray with Insecticide is a topical ectoparasiticide and antiseptic drug that is indexed under Minor Species Index File (MIF) 900-010 for use as a topical antiseptic for surface wounds, to repel flies, and to treat infestations due to fly strike in raptors, pet birds, captive small mammals, captive reptiles, and captive exotic/zoo mammals.³ F10 Antiseptic Wound Spray with Insecticide is not approved or indexed for the prevention and treatment of NWS myiasis.

Based on the totality of scientific evidence available to the FDA, including information submitted in support of MIF 900-010 and this EUA, as well as publicly available information, it is reasonable to believe that F10 Antiseptic Wound Spray with Insecticide may be effective for the prevention and treatment of infestations caused by NWS larvae (myiasis) in cattle, horses, minor species of hoof stock, raptors and other wild birds, pet birds, and captive wild, exotic, and zoo mammals, as described in this authorization, and when used under the conditions described in this authorization, the known and potential benefits of F10 Antiseptic Wound Spray with Insecticide outweigh the known and potential risks of such product.

Having concluded that the criteria for issuance of this authorization under Section 564(c) of the FD&C Act are met, I am authorizing the emergency use of F10 Antiseptic Wound Spray with Insecticide for the prevention and treatment of infestations caused by NWS larvae (myiasis) in cattle, horses, minor species of hoof stock, raptors and other wild birds, pet birds, and captive wild, exotic, and zoo mammals, as described in this authorization and subject to the terms of this authorization.

I. Criteria for Issuance of Authorization

I have concluded that the emergency use of F10 Antiseptic Wound Spray with Insecticide for the prevention and treatment of infestations caused by NWS larvae (myiasis) in cattle, horses, minor species of hoof stock, raptors and other wild birds, pet birds, and captive wild, exotic, and zoo mammals, when administered as described in this authorization, meets the criteria for issuance of an authorization under Section 564(c) of the FD&C Act, because:

1. NWS can cause a serious or life-threatening disease or condition to animals and humans;
2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe that F10 Antiseptic Wound Spray with Insecticide may be effective in preventing and treating NWS, and that, when used under the conditions and within the scope described in this authorization, the known and potential benefits of F10 Antiseptic Wound Spray with Insecticide when used to prevent and treat NWS outweigh the known and potential risks of such product; and
3. There is no adequate, approved, and available alternative to the emergency use of F10 Antiseptic Wound Spray with Insecticide for the prevention and treatment of infestations caused by NWS larvae (myiasis) in cattle, horses, minor species of hoof stock, raptors and other wild birds, pet birds, and captive wild, exotic, and zoo mammals.⁴

³ See FDA's webpage "The Index of Legally Marketed Unapproved New Animal Drugs for Minor Species" at <https://www.fda.gov/animal-veterinary/minor-use/minor-species/index-legally-marketed-unapproved-new-animal-drugs-minor-species>

⁴ No other criteria of issuance have been prescribed by regulation under Section 564(c)(4) of the FD&C Act.

Health and Hygiene (Pty) Ltd
Page 3
EUA 006672

II. Scope of Authorization

I have concluded, pursuant to Section 564(d)(1) of the FD&C Act, that the scope of this authorization is limited as follows:

- F10 Antiseptic Wound Spray with Insecticide, as covered by this authorization, will be used only for the prevention and treatment of infestations caused by NWS larvae (myiasis) in cattle, horses, minor species of hoof stock, raptors and other wild birds, pet birds, and captive wild, exotic, and zoo mammals; and
- The use of F10 Antiseptic Wound Spray with Insecticide covered by this authorization must be in accordance with the authorized Fact Sheet.

Product Description

F10 Antiseptic Wound Spray with Insecticide is a synthetic pyrethroid endoparasiticide with antiseptic. The authorized F10 Antiseptic Wound Spray with Insecticide bottle label is clearly marked for NWS under Emergency Use Authorization, with a website address and QR code that links to the authorized Fact Sheet.

Store between 15° to 30°C (59° to 86°F) in dry conditions.

F10 Antiseptic Wound Spray with Insecticide is authorized to be accompanied by the following product-specific information pertaining to emergency use, which is required to be made available to all users:

- Fact Sheet: Emergency Use Authorization of F10 Antiseptic Wound Spray with Insecticide (benzalkonium chloride, polyhexanide and cypermethrin topical solution) for New World Screwworm (NWS)

I have concluded, pursuant to Section 564(d)(2) of the FD&C Act, that it is reasonable to believe that the known and potential benefits of F10 Antiseptic Wound Spray with Insecticide, when used for the prevention and treatment of infestations caused by NWS larvae (myiasis) in cattle, horses, minor species of hoof stock, raptors and other wild birds, pet birds, and captive wild, exotic, and zoo mammals and used in accordance with this authorization, outweigh its known and potential risks.

I have concluded, pursuant to Section 564(d)(3) of the FD&C Act, based on the totality of scientific evidence available to FDA, that it is reasonable to believe that F10 Antiseptic Wound Spray with Insecticide may be effective for the prevention and treatment of infestations caused by NWS larvae (myiasis) in cattle, horses, minor species of hoof stock, raptors and other wild birds, pet birds, and captive wild, exotic, and zoo mammals when used in accordance with this authorization, pursuant to Section 564(c)(2)(A) of the FD&C Act.

Having reviewed the scientific information available to FDA, including the information supporting the conclusions described in Section I above, I have concluded that F10 Antiseptic Wound Spray with Insecticide, as described in this authorization, meets the criteria set forth in Section 564(c) of the FD&C Act concerning safety and potential effectiveness.

The emergency use of this product under an EUA must be consistent with, and may not exceed, the terms of this authorization, including the Scope of Authorization (Section II) and the Conditions of Authorization (Section III). Subject to the terms of this EUA and under the circumstances set forth in the Secretary of HHS's determination under Section 564(b)(1)(C) of the FD&C Act described above and the Secretary of HHS's corresponding declaration under Section 564(b)(1) of the FD&C Act, F10 Antiseptic Wound Spray with Insecticide is authorized for the prevention and treatment of infestations caused by NWS larvae (myiasis) in cattle, horses, minor species of hoof stock, raptors and other wild birds, pet birds, and captive wild, exotic, and zoo mammals as described in this authorization, despite the fact that it does not meet certain requirements otherwise required by applicable federal law.

III. Conditions of Authorization

Pursuant to Section 564 of the FD&C Act, I am establishing the following conditions on this authorization:

- A. Health and Hygiene will ensure that the authorized F10 Antiseptic Wound Spray with Insecticide, accompanied with the authorized Fact Sheet, is distributed to authorized distributor(s)⁵ consistent with the terms and conditions of this EUA, and that authorized distributor(s) will limit distribution to other authorized distributors and end users.
- B. Health and Hygiene will ensure that if a sticker is used on the bottle, the sticker contains a website address and QR code that link to the authorized Fact Sheet and that the sticker is placed in a blank space or does not obscure any important use or safety information.
- C. Health and Hygiene and authorized distributor(s) will ensure that appropriate storage conditions are maintained until the product is delivered to the end user.
- D. Health and Hygiene and authorized distributor(s) will provide to each authorized distributor immediately downstream in the supply chain a copy of this Letter of Authorization and promptly communicate any subsequent amendments that might be made to this Letter of Authorization and its authorized accompanying materials (e.g., its authorized Fact Sheet).
- E. Health and Hygiene may request changes to this authorization, including to the authorized Fact Sheet for F10 Antiseptic Wound Spray with Insecticide. Requests for changes must be submitted to the Office of New Animal Product Evaluation. Such changes require appropriate authorization prior to implementation.⁶
- F. Reporting Adverse Drug Experiences and Product/Manufacturing Defects:

⁵ The term "distributors" includes all parties in the supply chain between the recipient of this authorization letter and the end user, excluding veterinary facilities and veterinarians who only provide product to veterinarians and end users at their facility. "Authorized distributors" are all distributors who otherwise lawfully obtain and distribute the product, unless Health and Hygiene places limits on distribution in writing (e.g., via contract or written notice accompanying the product).

⁶ Changes that do not necessitate revision to this letter (e.g., changes to the Fact Sheet, changes related to current good manufacturing practice requirements, expiration dating extensions) may be authorized through separate notification without reissuance of this letter.

Health and Hygiene (Pty) Ltd
Page 5
EUA 006672

Health and Hygiene will report to FDA all product/manufacturing defects⁷ within 3 days, all serious adverse events⁸ and medication errors⁹ associated with the use of the authorized F10 Antiseptic Wound Spray with Insecticide that are reported to Health and Hygiene within 15 days, and all non-serious adverse drug events within 90 days. Submit the reports electronically using either of the following options which are described on FDA's Veterinary Adverse Event Reporting for Manufacturers webpage (www.fda.gov/IndustryReportAnimalAE).

Option 1: Submit reports through the Safety Reporting Portal (SRP).

Option 2: Submit reports directly through the Electronic Submissions Gateway (ESG).

Submitted reports must state in the "Narrative of Adverse Event" field: "F10 Antiseptic Wound Spray with Insecticide use for NWS under an EUA". Contact the Pharmacovigilance Liaison in CVM's Division of Pharmacovigilance and Surveillance at CVMAESupport@fda.hhs.gov for any questions related to electronic reporting or for assistance with setting up a Safety Reporting Portal account.

- G. Through a process of inventory control, Health and Hygiene and authorized distributor(s) will maintain records regarding distribution of the authorized F10 Antiseptic Wound Spray with Insecticide (i.e., lot numbers, quantity, receiving site, receipt date).
- H. Health and Hygiene and authorized distributor(s) will maintain records in connection with this EUA for at least two years following the termination of the declaration or the revocation of the authorization, or until notified by HHS or FDA, whichever is sooner, and will make such records available to FDA for inspection upon request.
- I. Health and Hygiene will comply with all other FD&C Act requirements applicable to the indexed product, F10 Antiseptic Wound Spray with Insecticide, including, but not limited to, requirements related to registration and listing, drug quality, and manufacturing process, facilities, and equipment in accordance with the index file¹⁰, unless such requirement is specifically waived or modified for the authorized product in this authorization. Health and

⁷ Product defect/manufacturing defect is the deviation of a distributed product from the standards specified in the indexed file, or any significant chemical, physical, or other change, or deterioration in the distributed drug product, including any microbial or chemical contamination. A manufacturing defect is a product defect caused or aggravated by a manufacturing or related process. A manufacturing defect may occur from a single event or from deficiencies inherent to the manufacturing process. These defects are generally associated with product contamination, product deterioration, manufacturing error, defective packaging, damage from disaster, or labeling error. For example, a labeling error may include any incident that causes a distributed product to be mistaken for, or its labeling applied to, another product.

⁸ Serious adverse event is an adverse event that is fatal, or life-threatening, or requires professional intervention, or causes an abortion, or stillbirth, or infertility, or congenital anomaly, or prolonged or permanent disability, or disfigurement.

⁹ Medication error is any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient, or consumer. Such events may be related to professional practice, health care products, procedures, and systems, including prescribing; order communication; product labeling, packaging, and nomenclature; compounding; dispensing; distribution; administration; education; monitoring; and use.

¹⁰ Changes shall be submitted and approved in accordance with 21 CFR 516.161 ("Modifications to indexed drugs"), unless otherwise approved under Condition E of this letter.

Health and Hygiene (Pty) Ltd
Page 6
EUA 006672

Hygiene shall update their drug listing to reflect the EUA, including submission of updated labeling, before commercial distribution of the EUA product begins.

Conditions of Authorization Related to Advertisements and other Promotional Descriptive Printed Matter

- J. All advertisements (including printed and nonprinted communications) and other promotional descriptive printed matter relating to the authorized use of F10 Antiseptic Wound Spray with Insecticide shall be consistent with the authorized Fact Sheet¹¹ and the terms set forth in this EUA, as well as comply with FD&C Act section 502(a). Additionally, the sponsor and authorized distributor(s) shall comply with any other applicable requirements in the FD&C Act and its implementing regulations regarding advertising and/or promotion.
- K. Health and Hygiene and authorized distributor(s) may not imply that F10 Antiseptic Wound Spray with Insecticide is FDA approved, conditionally approved, or indexed for the authorized use by making statements such as "F10 Antiseptic Wound Spray with Insecticide is safe and effective for the prevention and treatment of infestations caused by New World screwworm (*Cochliomyia hominivorax*) larvae (myiasis) in cattle, horses, minor species of hoof stock, raptors and other wild birds, pet birds, and captive wild, exotic, and zoo mammals". Health and Hygiene and authorized distributor(s) may disseminate advertisements (including printed and nonprinted communications) and other promotional descriptive printed matter relating to the emergency use of F10 Antiseptic Wound Spray with Insecticide that provide accurate descriptions of safety and effectiveness information summarized in the authorized Fact Sheet. Such materials must include any limitations of information submitted to support this authorization.
- L. All advertisements (including printed and nonprinted communications) and other promotional descriptive printed matter relating to the authorized use of F10 Antiseptic Wound Spray with Insecticide shall be accompanied by the authorized Fact Sheet, and shall clearly and conspicuously state that:
- F10 Antiseptic Wound Spray with Insecticide has not been approved or indexed for the prevention and treatment of infestations caused by NWS myiasis in cattle, horses, minor species of hoof stock, raptors and other wild birds, pet birds, and captive wild, exotic, and zoo mammals;
 - F10 Antiseptic Wound Spray with Insecticide has been authorized by FDA under an EUA for the prevention and treatment of infestations caused by NWS myiasis in cattle, horses, minor species of hoof stock, raptors and other wild birds, pet birds, and captive wild, exotic, and zoo mammals; and
 - F10 Antiseptic Wound Spray with Insecticide is authorized as described herein only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of F10 Antiseptic Wound Spray with Insecticide under Section 564(b)(1)

¹¹ If the authorized Fact Sheet references sections of the drug's labeling (as contained in its index listing), the entirety of each section is considered part of the Fact Sheet, except as otherwise specified. Advertising and promotional materials may not use general references to the labeling in lieu of summarizing or restating its contents when a summary or restatement is otherwise needed to comply with applicable requirements.

Health and Hygiene (Pty) Ltd
Page 7
EUA 006672

of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or the authorization is revised or revoked sooner.

- M. All advertisements (including printed and nonprinted communications) and other promotional descriptive printed matter must be submitted to your Type VII Veterinary Master File as a G submission at the time of initial dissemination (publication or broadcast). When submitting, identify the submission as promotion and advertising material.

If FDA notifies Health and Hygiene or authorized distributor(s) that any descriptive materials, advertising, or promotional materials do not meet the terms set forth in this EUA, Health and Hygiene or authorized distributor(s) must discontinue and/or cease distribution of such advertisements (including printed and nonprinted communications) and other promotional descriptive printed matter in accordance with FDA's notification. Furthermore, as part of its notification, FDA may also require Health and Hygiene or authorized distributor(s) to issue corrective communication(s).

IV. Duration of Authorization

This EUA will be effective as described herein until the declaration that circumstances exist justifying the authorization of the emergency use of animal drugs during the NWS public health emergency is terminated under Section 564(b)(2) of the FD&C Act or the EUA is revised or revoked under Section 564(g) of the FD&C Act.

Sincerely,

{see appended electronic signature page}

Timothy Schell, Ph.D.
Director
Center for Veterinary Medicine
U.S. Food and Drug Administration

Enclosures:
Freedom of Information Summary
Fact Sheet

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20903
www.fda.gov

Grace R. Graham,
*Deputy Commissioner for Policy, Legislation,
and International Affairs.*

[FR Doc. 2026-07509 Filed 4-16-26; 8:45 am]

BILLING CODE 4164-01-C

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2011-N-0655]

Animal Generic Drug User Fee Act; Public Meeting; Request for Comments

AGENCY: Food and Drug Administration,
HHS.

ACTION: Notice of public meeting;
request for comments.

SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is announcing the following virtual public meeting entitled "Animal Generic Drug User Fee Act." The purpose of the public meeting is to invite public comment on the Animal Generic Drug User Fee Act (AGDUFA)